Macrophage migration inhibitory factor contributes to the severity of Alphaviral induced disease
Lara J. Herrero(Griffith University), Eric F. Morand(Novartis (Switzerland)), Suresh Mahalingam(Griffith University), Leilani L. Santos(Royal Women's Hospital), Michelle Nelson(Defence Science and Technology Laboratory), Riliang Gu(Ministry of Agriculture and Rural Affairs)
Unknown
January 1, 2010
Cited by 0
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726